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a higher incidence of rejection and infection than other
solid organ transplants. Most current clinical protocols
include some combination of cyclosporine (INN: ciclo-
sporin) (or most recently tacrolimus), corticosteroids,
azathioprine, and occasionally antilymphocyte prepara-
tions. Although the use of cyclosporine has allowed
L ung transplantation has become an accepted form oftreatment for many types of end-stage lung disease.
This has been a consequence, in part, of improvements
in organ preservation, surgical technique, postoperative
care, and immunosuppression. Despite these improve-
ments, lung transplantation continues to be plagued by
Background: Cyclosporine-based immunosuppressive regimens (INN:
ciclosporin) in human lung transplantation continue to result in a high
incidence of acute cellular rejection. We investigated the use of siro-
limus, a macrolide with structural similarity to tacrolimus, as mono-
therapy and in combination with cyclosporine in a rodent lung trans-
plant model. Methods: Orthotopic left lung transplantation was
performed in Lewis recipients from Brown-Norway donor rats with syn-
geneic Lewis-to-Lewis controls. Open biopsies were performed on post-
operative day 7, and the severity of acute lung rejection was graded by
a pathologist blinded to the protocol. Results: All recipients survived
despite the amount of acute rejection seen on examination of the biopsy
tissue. Lewis-to-Lewis isografts demonstrated near normal pulmonary
architecture. Allogeneic recipients receiving high-dose cyclosporine (25
mg/kg) monotherapy showed mild to moderate acute rejection with
some perivascular focal interstitial infiltrates. Recipients receiving low-
dose cyclosporine (5 mg/kg) monotherapy or low- or high-dose sirolimus
(0.5 or 2.0 mg/kg, respectively) monotherapy demonstrated massive cel-
lular infiltration leading to necrosis and infarction and could not be
graded. However, the addition of low-dose sirolimus (0.5 mg/kg) to low-
dose cyclosporine (5 mg/kg) demonstrated a significant potentiating im-
munosuppressive effect, and the addition of high-dose sirolimus (2.0
mg/kg) to low-dose cyclosporine (5.0 mg/kg) demonstrated an even
greater effect, with rejection scores better than those obtained with
high-dose cyclosporine monotherapy and similar to those obtained with
isografts. Conclusions: This study demonstrates that low-dose sirolimus
has a cyclosporine-sparing effect and that a higher dose of sirolimus in
combination with cyclosporine strongly protects lung allografts from
acute cellular rejection. These results suggest that sirolimus may be
indicated as an adjunct to current cyclosporine-based immunosuppres-
sive regimens in clinical lung transplantation. (J Thorac Cardiovasc
Surg 1999;117:714-8)
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tremendous advances in transplantation, acute allograft
rejection and subsequently the long-term complication
of obliterative bronchiolitis remain major obstacles in
clinical lung transplantation. New immunosuppressive
agents or combinations of agents for pulmonary allo-
grafts need to be evaluated.
Sirolimus is a macrolide isolated from the actino-
mycete Streptomyces hygroscopicus with some struc-
tural similarity to tacrolimus.1 The drug acts between
the G1 and S phase of the T-cell activation cascade, can
act directly on both T cells and B cells, and can strongly
suppress in vitro immunoglobulin production.2,3 Al-
though structurally related to tacrolimus, sirolimus does
not inhibit interleukin-2 production but inhibits the pro-
liferative response of T cells to interleukin-2 and other
cytokines. Sirolimus has been used as an effective
immunosuppressive agent after skin, heterotopic and
vascularized heart, pancreas, kidney, and small bowel
transplantation in the rat.1,4 However, sirolimus has not
been used in clinical lung transplantation, in part,
because of the paucity of its use in animal transplant
models.
We investigated the addition of sirolimus to cyclo-
sporine and hypothesized that this immunosuppressive
combination would result in an additive immunosup-
pressive effect and demonstrate a cyclosporine-sparing
effect in a rat model of orthotopic acute lung transplant
rejection.
Materials and methods
Orthotopic left lung transplantation was performed in
Lewis recipients from Brown-Norway donor rats (Charles
River, NJ). Animals were assigned into 8 groups. Syngeneic
transplantation of Lewis to Lewis without any immunosup-
pression (group A, n = 8) served as a “negative” control.
Allogeneic transplantation of Brown-Norway to Lewis with-
out any immunosuppression (group B, n = 6) served as a
“positive” control. There were 6 experimental groups (total n
= 37) randomly assigned to receive immunosuppressive ther-
apy with intramuscular cyclosporine (Cremaphor-based,
Sandimmune, Novartis Pharma, East Hanover, NJ), mono-
therapy (group C, 5 mg/kg per day; group D, 25 mg/kg per
day); intraperitoneal sirolimus (Wyeth-Ayerst Research
Laboratories, Philadelphia, Pa) monotherapy (group E, 0.5
mg/kg per day; group F, 2.0 mg/kg per day); or a combination
of cyclosporine plus sirolimus (group G, 5 mg/kg per day/0.5
mg/kg per day; group H, 5 mg/kg per day/2.0 mg/kg per day).
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” published by the
National Society for Medical Research and the “Guide for the
Care and Use of Laboratory Animals” (National Institutes of
Health publication No. 86-23, revised 1985).
All animals (n = 51) underwent left orthotopic lung trans-
plantation by means of the microvascular technique described
previously in the literature.5,6 The donor procedure was per-
formed concurrently to minimize the ischemic period of the
pulmonary allograft. Donor rats were lightly anesthetized by
inhalation of methoxyflurane in a sealed glass enclosure. The
rats were premedicated by intramuscular injection of atropine
(0.25 mg/kg), and operative anesthesia was achieved with
intraperitoneal administration of pentobarbital (50 mg/kg). A
tracheostomy was performed and a 14-gauge angiocatheter
was inserted to institute positive-pressure ventilation. The
animal was connected to a rodent ventilator that was adjusted
to maintain normal ventilation (respiratory rate 70 breaths/
min; tidal volume 10 ml/kg body weight; peak inspiratory
pressure 20 cm H2O). Through a median sternotomy, the tho-
racic organs were exposed and the inferior pulmonary liga-
ments incised. The donor animals received 300 units of intra-
venous heparin. A 16-gauge catheter was inserted into the
main pulmonary artery through the right ventricular outflow
tract. The inferior and superior venae cavae were divided and
the left atrial appendage amputated. The pulmonary artery
was then flushed with cold Euro-Collins solution (100 ml/kg)
from a height of 30 cm, and the thorax was irrigated with cold
(4°C) normal saline solution. A hemostatic clip was placed
across the trachea to maintain lung inflation and the donor
heart and lungs were removed en bloc. The left lung was dis-
sected by dividing the hilar vessels and left main bronchus as
proximally as possible to obtain sufficient length for the anas-
tomosis. The left lung was kept inflated by placing a hemo-
static clip across the proximal left main bronchus. The left
lung block was then wrapped in a bed of gauze soaked with
preservation solution and placed in a plastic container sur-
rounded by ice and maintained at 4°C for the remainder of
the ischemic storage period.
Recipient rats were lightly anesthetized by inhalation of
methoxyflurane in a sealed glass enclosure. The rats were
premedicated by intramuscular injection of atropine (0.25
mg/kg), and operative anesthesia was achieved with intraperi-
toneal administration of pentobarbital (50 mg/kg). The ani-
mal was orally intubated with a 14-gauge angiocatheter,
placed in the right lateral decubitus position, and then con-
nected to a rodent ventilator (respiratory rate 70 breaths/min;
tidal volume 10 ml/kg body weight; peak inspiratory pressure
20 cm H2O) with operative anesthesia maintained with
halothane 0.5% to 1.0%. A left thoracotomy was performed
at the fifth intercostal space. The inferior pulmonary ligament
was incised and the hilar structures were dissected. The left
pulmonary artery, left pulmonary vein, and left main stem
bronchus were clamped with microvascular clamps and the
native left lung was excised. The pulmonary vein and artery
were anastomosed at the hilum sequentially with 10-0 and 9-
0 nylon sutures, respectively, in an interrupted fashion. The
vascular clamps were then removed and reperfusion was
established. The bronchial anastomosis was completed with a
9-0 nylon continuous suture. The lungs were then hyperin-
flated to remove atelectasis from the donor lung. A tube tho-
racostomy was then placed with the use of a 14-gauge sili-
cone rubber catheter, and the thoracotomy incision was
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closed in 3 layers. When the rats resumed spontaneous respi-
ration, the tube thoracostomy and orotracheal tube were
removed. The animals were allowed to recover after the oper-
ation in a heated, humidified chamber. The animals were then
placed in clean cages after their recovery period and were
provided food and water ad libitum.
The recipients received immunosuppression as previously
outlined, and open lung biopsies were then performed on
postoperative day 7. The open lung biopsy tissue was snap
frozen in liquid nitrogen, and frozen section analysis with
hematoxylin and eosin staining was performed. Acute lung
rejection was graded by a pathologist blinded to the protocol,
who was using a modified version of the Working Formu-
lation Lung Rejection Study Group7: 0, no significant abnor-
mality; 1, minimal acute rejection; 2, mild acute rejection; 3,
moderate acute rejection; 4, severe acute rejection; and X,
complete rejection of the graft with massive cellular infiltra-
tion that could not be assigned a grade. Rejection scores were
then tabulated and analyzed.
Groups were compared by means of Fisher’s exact test (2-
tailed) based on a hypergeometric distribution. Pairwise com-
parisons of the various treated groups versus the syngeneic
control group were considered significant if the P value was
less than .0167 (traditional a = .05/3 pairwise comparisons).
Pairwise comparisons between the treated groups were con-
sidered significant if the P value was less than .05.
Results
All recipients survived despite the amount of acute
rejection seen on biopsy tissue. Biopsy rejection scores
are tabulated and represented in Table I. Syngeneic
Lewis-to-Lewis transplants had a mean rejection score
(± standard deviation) of 0.25 ± 0.46 (median = 0) and
demonstrated near normal pulmonary architecture.
Brown-Norway–to–Lewis allografts without immuno-
suppression had massive cellular infiltration leading to
infarction and necrosis within 7 days. Recipients
receiving cyclosporine 25 mg/kg monotherapy had a
rejection score of 2.71 ± 0.49 (median = 3), demon-
strating a mild to moderate amount of acute rejection
with some perivascular focal interstitial infiltrates.
Recipients receiving monotherapy consisting of cyclo-
sporine 5 mg/kg, sirolimus 0.5 mg, or sirolimus 2.0 mg
demonstrated massive cellular infiltration leading to
necrosis and infarction and could not be graded. The
addition of low-dose sirolimus 0.5 mg/kg to low-dose
cyclosporine 5 mg/kg demonstrated a significant poten-
tiating immunosuppressive effect with a mean rejection
score of 2.29 ± 0.76 (median = 2), which was not sta-
tistically different from that of the high-dose cyclo-
sporine monotherapy group (P = .592). Furthermore,
the addition of high-dose sirolimus at 2.0 mg/kg to
low-dose cyclosporine at 5.0 mg/kg demonstrated an
even greater protective effect with a mean rejection
score of 0.25 ± 0.50 (median = 0), which is superior to
low-dose sirolimus/low-dose cyclosporine therapy (P =
.018), superior to high-dose cyclosporine monotherapy
(P = .003), and similar to results in isograft controls
(P = 1.0).
Discussion
With improvements in survival, lung transplantation
has become an accepted therapeutic option for patients
with end-stage pulmonary disease. Cyclosporine-based
immunosuppression protocols have resulted in a
greater than 70% 1-year survival at major lung trans-
plant centers.8 Despite these impressive results, the
incidence of acute rejection episodes during the first
100 postoperative days is greater than 75% incidence.
Infection continues to be the leading cause of death
during the first year and appears to be due in part to the
treatment of these acute rejection episodes. As has been
Table I. Effects of low- and high-dose cyclosporine and sirolimus monotherapy and combination therapy on lung
allograft rejection scores
Rejection grade 
Group Donor Recipient Immunosuppression Rejection grade (mean ± SD) Median Range
A LEW LEW None 0.25 ± 0.46 0 0-1
B BN LEW None X X
C BN LEW CsA 5 mg/kg X X
D BN LEW CsA 25 mg/kg 2.71 ± 0.49 3 2-3
E BN LEW Siro 0.5 mg/kg X X
F BN LEW Siro 2.0 mg/kg X X
G BN LEW CsA 5 mg/kg + Siro 0.5 mg/kg 2.29 ± 0.76 2 1-3
H BN LEW CsA 5 mg/kg + Siro 2.0 mg/kg 0.25 ± 0.50 0 0-1
BN, Brown-Norway; LEW, Lewis: CsA, cyclosporine; Siro, sirolimus; X, complete rejection of graft with massive cellular infiltration and could not be assigned a
grade. Group A versus group D (P < .001); group A versus group G (P = .002); group A versus group H (P = 1.0). Group D versus group G (P = .592); group D ver-
sus group H (P = .003). Group G versus group H (P = .018).
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previously demonstrated,9 obliterative bronchiolitis is
the leading cause of death in patients surviving more
than 1 year after transplantation, and acute rejection is
one of the most significant risk factors and may be a
marker for the development of obliterative bronchioli-
tis.9,10 It is apparent that what is required for continued
improvement in long-term survival of recipients of lung
transplants are immunosuppressive drug combinations
that maximize immunosuppressive efficacy and mini-
mize toxicity.
The present study examined the addition of sirolimus
to cyclosporine in an orthotopic lung transplant model.
To our knowledge, this is the first study in which this
immunosuppressive combination has been used in a
fully vascularized rat orthotopic lung transplant model.
The results demonstrate that effective immunosuppres-
sion can be obtained when sirolimus is used in combi-
nation with cyclosporine and that the lung allograft is
strongly protected from acute cellular rejection, as evi-
denced by histologic evaluation. Ochiai and associ-
ates11 demonstrated in a rat cardiac allograft model that
sirolimus at 0.1 mg/kg for 11 days had a marginal effect
on mean survival time, whereas the addition of cyclo-
sporine at 3.2 mg/kg to sirolimus resulted in indefinite
graft survival time. Similarly, Chen and coworkers12
demonstrated that the combination of cyclosporine 2
mg/kg and sirolimus 0.08 mg/kg significantly pro-
longed the survival time of pancreaticoduodenal allo-
grafts in the rat when compared with low-dose therapy
of these agents individually. Our data demonstrate the
effectiveness of sirolimus administered at 2 mg/kg
when used in combination with cyclosporine 5 mg/kg,
with rejection scores that are similar to those of lung
isografts.
The toxicity of cyclosporine, in particular impaired
renal function and hypertension, limits increases in
dosages to prevent rejection. Therefore any immuno-
suppressive regimen that can maximize the net thera-
peutic index of cyclosporine while limiting its toxicity
by having a sparing effect would be beneficial. The
ability of small doses of sirolimus to produce synergis-
tic immunosuppression has been evaluated in human
lymphocytes in vitro.13 Knight and colleagues14
demonstrated consistent prolongation of renal allograft
survival in the mongrel canine model. Sirolimus at 0.05
mg/kg per day was added to subtherapeutic doses of
cyclosporine, and this was found to potentiate the
immunosuppressive effect in this model, with a mean
allograft survival time of 75 ± 14.3 days. This syner-
gistic effect was again demonstrated in a study of heart
and kidney allograft models in rats.15 In every
sirolimus/cyclosporine dose combination, allografts
survived significantly longer than in recipients treated
with a single drug. Furthermore, increased sirolimus/
cyclosporine doses resulted in increased prolongation
of heart allograft survival. Similar results were
obtained in our present study, in which the addition of
low-dose sirolimus (0.5 mg/kg) to low-dose cyclo-
sporine (5 mg/kg) resulted in lung allograft rejection
scores similar to those of high-dose cyclosporine. In
addition, the potentiating and cyclosporine-sparing
effects were demonstrated when the sirolimus dose was
increased to 2.0 mg/kg, with rejection scores signifi-
cantly better than those obtained with high-dose
cyclosporine and similar to those obtained with iso-
grafts.
As demonstrated previously,4 sirolimus at intra-
venous doses as low as 0.08 mg/kg per day significant-
ly prolonged cardiac and renal allograft survival,
whereas 0.8 mg/kg per day was necessary to prolong
small bowel allograft survival in rats. Sirolimus thera-
py showed a dose-dependent response with the highest
tested dose of 0.8 mg/kg producing heart allograft sur-
vival of 48 ± 3.6 days. This prior work demonstrated
the efficacy of sirolimus as monotherapy in the rat
heart, kidney, pancreas, and small bowel transplant
models. However, in our study, a similar efficacy could
not be demonstrated in the rat orthotopic lung trans-
plant model. Low and high doses of sirolimus were
used as monotherapy and resulted in complete rejection
of the lung allograft in each study group. Perhaps the
lung is a more immunogenic organ allograft and re-
quires more intensive immunosuppressive regimens.
This might explain the higher incidence of rejection in
clinical lung transplants when compared with other
solid organ transplants.
Limitations of this study include the fact that this was
purely a study of acute rejection. We investigated only
one aspect of acute rejection, that being histologic eval-
uation. It remains to be investigated whether the addi-
tive effect of sirolimus to cyclosporine correlates with
long-term graft acceptance. Another limitation of the
study was that it did not evaluate the function of the
allograft. Although the graft appeared to be viable on
sectioning, with the appearance of normal pulmonary
architecture, it was not determined whether indeed the
graft retained its gas exchange capabilities. Finally,
combining sirolimus with tacrolimus was not evaluated
in this study. This will need to be further investigated
because there is increasing clinical experience with
tacrolimus-based immunosuppression in lung trans-
plant recipients. In future experimental and clinical
studies, for both tacrolimus- and cyclosporine–based
regimens in which sirolimus is added, blood levels of
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these drugs should be measured to assess potential
pharmacokinetic interactions.
In summary, lung transplantation is associated with
gradually improving survival statistics that have been
obtained with both cyclosporine- and tacrolimus-based
immunosuppressive regimens. However, obliterative
bronchiolitis continues to be the major long-term com-
plication and appears to be a sequela of acute rejection
episodes that remains common in lung transplantation.
We have evaluated the efficacy of sirolimus as an
adjunct to cyclosporine in preventing acute lung rejec-
tion in the rat orthotopic lung transplant model. Also,
we have shown that the potentiating and cyclosporine-
sparing effect of sirolimus previously demonstrated in
other vascularized organ transplant models is relevant
to an experimental lung transplant model. However, we
could not demonstrate the efficacy of sirolimus
monotherapy as has been suggested by prior studies in
nonpulmonary models. In light of the results of this
study, combined with increasing clinical experience
and safety of sirolimus in human renal transplantation
studies, we believe that the combination of sirolimus
and cyclosporine may be very promising for clinical
lung transplantation.
We thank Suren N. Sehgal, PhD (Wyeth-Ayerst Research
Laboratories), for his assistance with providing sirolimus and
for his expertise.
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